about
Type 1 diabetesImmune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD MiceAddition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.Testing agents for prevention or reversal of type 1 diabetes in rodents.Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 DiabetesDevelopment of standardized insulin treatment protocols for spontaneous rodent models of type 1 diabetes.Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetesKnockout mouse models of insulin signaling: Relevance past and futureAnimal models of human type 1 diabetes for evaluating combination therapies and successful translation to the patient with type 1 diabetes.Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs under Development.A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future.
P2860
Q27000491-CA25B572-38BC-4878-879E-94CAD7C90050Q28551036-1BE0E1CE-80B8-4068-9CD4-74E2689C8BADQ34796651-FFAEE8A6-2665-4678-8938-D848360B9CA2Q34983677-5E5CD116-B66E-420F-8CB2-D37F12FCFA14Q35146734-400392AC-5571-46BA-9526-F39A660B8F7FQ36186226-A66DE1BD-3BF6-42B3-ACAC-E618C77F971EQ36186271-74195333-860E-4225-914E-896B159BAC21Q36321376-CDE704DB-5E61-4232-A468-89015A74B786Q37088185-6B95FDF0-A62C-4087-8C6C-E82638690244Q38205763-26F7DE99-8BD4-462B-A4EF-079162252F96Q38660322-E20327CA-92CD-4A17-A2BC-D9B13F75791AQ38806457-EF4476C9-2807-4EAF-980F-F0658D13F226Q38926045-AF078F12-3EB2-4D96-90BC-77EEEE0923ACQ50987368-8E90CE5E-D875-4E7A-8B05-1A9E1BA46E66Q51149244-0074370C-604D-4273-8CF6-D3D9DA611AA7
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluating preclinical efficacy.
@ast
Evaluating preclinical efficacy.
@en
Evaluating preclinical efficacy.
@nl
type
label
Evaluating preclinical efficacy.
@ast
Evaluating preclinical efficacy.
@en
Evaluating preclinical efficacy.
@nl
prefLabel
Evaluating preclinical efficacy.
@ast
Evaluating preclinical efficacy.
@en
Evaluating preclinical efficacy.
@nl
P2860
P1476
Evaluating preclinical efficacy.
@en
P2093
Mark A Atkinson
P2860
P304
P356
10.1126/SCITRANSLMED.3002757
P407
P577
2011-08-01T00:00:00Z